Preeclampsia discovery could lead to new test and treatments for at-risk pregnancies
· Medical Xpressedited by Sadie Harley, reviewed by Robert Egan
Sadie Harley
Scientific Editor
Meet our editorial team
Behind our editorial process
Robert Egan
Senior Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
peer-reviewed publication
trusted source
proofread
The GIST Add as preferred source
Cambridge scientists have identified a key protein that could act as a predictor for preeclampsia and fetal growth restriction, two of the major causes of stillbirth and illness among mothers and newborns. The discovery helps explain why placental cells fail to properly "invade" the uterus in these related conditions and could lead to tests that help identify those at greatest risk and new treatments. The findings are published in Nature Medicine.
Preeclampsia affects around one in 20 pregnancies worldwide and is a leading cause of maternal and fetal health complications, contributing significantly to mortality among mothers and babies worldwide.
Fetal growth restriction, in which a baby does not reach its biological growth potential in the womb, affects roughly 3% to 10% of pregnancies in high-income countries and up to one in five pregnancies globally. It is a leading cause of complications during pregnancy and in newborns, including stillbirth.
Both conditions are known to be linked to problems with the placenta not developing properly early in pregnancy, particularly a failure of specialized placental cells known as extravillous trophoblasts (EVT) to invade the mother's womb and establish a healthy blood supply.
When placental invasion breaks down
Professor Gordon Smith, head of the Department of Obstetrics and Gynecology at the University of Cambridge, said, "As part of normal development, the placenta invades the tissues of the mother's womb. Of all mammals, humans have the deepest placental invasion, which reflects the massive demands for oxygen and nutrients required to manufacture the most complex machine ever known, the human brain.
"When this process goes wrong and specialist placental cells fail to adequately invade the uterus, it results in a placenta and fetus that are deprived of nutrients and oxygen, leading to preeclampsia and fetal growth restriction. But until now, the reason for this failed invasion has been obscure."
To better understand this process, Smith and colleagues from the Department of Obstetrics and Gynecology and The Loke Center for Trophoblast Research at the University of Cambridge analyzed serum samples taken from pregnant women around week 12 of pregnancy.
The women had been recruited to the Pregnancy Outcome Prediction Study (POPS) at the Rosie Hospital, part of Cambridge University Hospitals NHS Foundation Trust.
The researchers looked retrospectively for "red flags" present in women whose pregnancies went on to be affected by preeclampsia or fetal growth restriction.
Low ISM2 stood out early
The researchers found that low circulating levels of a protein known as isthmin-2 (ISM2) around three months into pregnancy were the strongest indicator that a pregnancy would go on to face problems with preeclampsia or fetal growth restriction.
ISM2 and its associated mRNA—a molecule that carries instructions from DNA to the part of the cell that makes proteins—are produced almost exclusively in the placenta. Within the placenta, ISM2 mRNA is found in the greatest abundance in EVTs.
To test whether this association was likely to be a cause of the problems, the team used a laboratory technique to switch off or greatly reduce production of ISM2 in human trophoblast stem cells. The trophoblast is the outer layer of the early-stage embryo, and these stem cells can normally develop into the outer layer of the placenta. However, although the cells still survived and grew normally in the absence of ISM2, they failed to turn into invasive EVT cells.
In 3D cellular models known as placental organoids—essentially, "mini-placentas"—the cells stopped spreading into surrounding material that mimicked the uterus. In other words, without ISM2, the cells lose their ability to become the type of cells that burrow into the womb and establish blood flow.
Remarkably, when human kidney cells—which do not normally make the protein—were forced to make ISM2, they became more invasive in cell culture.
A marker with treatment potential
Smith, who is also a consultant in maternal and fetal medicine at The Rosie, added, "This has major implications for care in pregnancy. Early-pregnancy maternal levels of isthmin-2 are much better at predicting complications than existing tests, so it could enable us to develop better ways of identifying pregnancies at greatest risk.
"It also gives us a potential way to prevent these conditions from happening, if we can find a way to stimulate production of ISM2 in the placenta. Not only that, but blocking it might prevent the need for surgery for complications in which the placenta has implanted in the wrong place, such as ectopic and Cesarean scar pregnancies."
Professor Steve Charnock-Jones, from the Department of Obstetrics and Gynecology, said, "Every pregnancy carries with it a risk of preeclampsia and fetal growth restriction, and this is even more the case in low- and middle-income countries. Now that we know what goes wrong, we may be in a better position to make a major difference to pregnancy outcomes, protecting the health and lives of millions of mothers and their babies every year."
The researchers identified the protein by studying a sample of more than 200 women who subsequently experienced preeclampsia and/or fetal growth restriction and more than 200 women with normal pregnancies. The findings were validated by studying samples from Swedish pregnant women, including more than 100 cases and 200 controls.
Publication details
Miao, R, et al. Isthmin-2 is essential for extravillous trophoblast invasion and is a first trimester predictor of preeclampsia and fetal growth restriction, Nature Medicine (2026). DOI: 10.1038/s41591-026-04573-6
Journal information: Nature Medicine
Key medical concepts
Fetal Growth RetardationPreeclampsia
Clinical categories
Obstetrics & gynecologyPregnancyWomen's health Provided by University of Cambridge Who's behind this story?
Sadie Harley
BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: Preeclampsia discovery could lead to new test and treatments for at-risk pregnancies (2026, September 1) retrieved 1 September 2026 from https://medicalxpress.com/news/2026-08-preeclampsia-discovery-treatments-pregnancies.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.